A donation of $25 will fund one hour for a post-doctoral Fellow. Donors, who permit recognition, will be named as "Post-Doc Supporters" on the AUSiMED's website.
Donations are used to develop a critically needed new breast cancer treatment. This treatment is for women with breast cancer that is resistant to all forms of treatment. As a result they have no prospect of survival. In Australia, this is around 20% of breast cancer patients (almost 3000 deaths in 2011).
Surviving breast cancer is an issue for women with inherited BRCA1 and BRCA 2 mutated genes. Their tumours tend to become resistant to all forms of treatment.
Angelina Jolie inherited a BRCA1 mutated gene. Her risk of getting breast cancer from this mutated gene was over 90%. Her risk of getting ovarian cancer was over 50%. Also, because women with this mutated gene tend to be resistant to all forms of treatment, Angelina recently had both her breasts and her ovaries removed to prevent getting breast and ovarian cancer.
Inherited BRCA1 and 2 mutated genes is a major issue for the Jewish community as 1 in 40 (2.5%) of Ashkenazi Jewish women worldwide carry the mutated genes which is 10 times more prevalent amongst Ashkenazi Jews than the rest of the population.
AUSiMED has identified an outstanding research team in Australia at the Walter and Eliza Hall Institute in Melbourne as well as in Israel at the Sheba Medical Centre in Tel Aviv. Both teams have exceptional track records of success and have together developed an exciting collaborative research project to find out how breast cancers become resistant to treatments and how to stop this resistance process. The project is so impressive that the Australian team have been recently awarded with two years of funding for the proposed project by the National Breast Cancer Foundation. AUSiMED is now seeking to raise funds for the Israeli team, so they can participate in this project as well.